Dual effects of baicalin on osteoclast differentiation and bone resorption

Xuanyuan Lu, Wei He, Wanlei Yang, Jianlei Li, Weiqi Han, Qian Liu, Tan Zhang, Jiawei Jiang, An Qin, Yu QianJournal of Cellular and Molecular Medicine 2018 · DOI

TL;DR

This study reveals that baicalin, a natural compound, exhibits a dual effect on osteoclast activity: low concentrations promote bone resorption, while high concentrations inhibit it. This dose-dependent action, mediated by the ERK/c-Fos/NFATc1 pathway, has significant implications for treating bone diseases and highlights the importance of precise dosing for therapeutic agents.

What Problem Does This Paper Address?

Bone homeostasis is a delicate balance maintained by osteoblasts (bone formation) and osteoclasts (bone resorption). Dysregulation of osteoclast activity is implicated in various bone diseases, most notably osteoporosis, where excessive bone resorption leads to weakened bones. Conversely, insufficient osteoclast activity can result in osteosclerosis, characterized by increased bone mass. Therefore, identifying agents that can precisely modulate osteoclast function is crucial for developing effective treatments for a spectrum of bone disorders. While many compounds have been investigated for their effects on osteoclasts, understanding their dose-dependent actions and underlying mechanisms is essential for safe and effective therapeutic application. This paper specifically investigates the effects of baicalin, a flavonoid with known anti-inflammatory and antioxidant properties, on osteoclast differentiation and function, aiming to clarify its complex, concentration-dependent role.

Methods

The researchers employed a multi-faceted approach to investigate baicalin's effects:

  • In vitro studies:
    • Osteoclast differentiation: Mouse bone marrow-derived macrophages (BMMs) were cultured and induced to differentiate into osteoclasts using RANKL and M-CSF. Baicalin was added at various concentrations to assess its impact on differentiation.
  • TRAP staining and activity assay: Tartrate-resistant acid phosphatase (TRAP) is a marker for osteoclasts. Staining was used to identify and quantify osteoclasts, and its activity was measured.
  • Actin ring and pit formation assays: F-actin rings are crucial for osteoclast function and bone resorption. Their formation was visualized using phalloidin staining. Pit formation assays on bone slices, visualized by scanning electron microscopy, directly assessed bone resorption activity.
  • Western Blotting: This technique was used to analyze the expression and phosphorylation of key signaling proteins involved in osteoclastogenesis, including MAPK (ERK), PI3K/Akt, NF-κB, c-Fos, and NFATc1.
  • Real-time PCR: Gene expression of osteoclast-specific markers (TRAP, Ctsk, V-ATPase d2, MMP-9) was quantified.
  • Apoptosis assays: Levels of apoptosis-related proteins (Bcl-2, Bax, caspase-3) were measured to understand baicalin's impact on cell survival.
  • Cytotoxicity assay (MTT): This assay determined the safe concentration range of baicalin for the cells.
  • In vivo studies:
    • LPS-induced calvarial osteolysis model: This established animal model mimics inflammatory bone loss. Mice were treated with lipopolysaccharide (LPS) to induce osteolysis, with or without different doses of baicalin.
  • Micro-computed tomography (Micro-CT): This imaging technique was used to assess bone volume and resorption area in the calvaria of treated mice.
  • Histological analysis: Hematoxylin and eosin (H&E) staining and TRAP staining were performed on calvarial bone sections to visualize bone structure and identify osteoclasts.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from cell cultures and animal models.

Key Insights and Ideas

  • Baicalin's "Jekyll and Hyde" effect: The most striking finding is baicalin's dual, concentration-dependent action. It's not simply a promoter or inhibitor of osteoclasts; its effect flips based on how much is present. This is crucial for understanding its therapeutic potential and risks.
  • ERK pathway as a key mediator: The study strongly implicates the MAPK (ERK) signaling pathway as the central player in baicalin's dual effect. Low doses activate it, promoting osteoclastogenesis, while high doses suppress it, leading to inhibition. This provides a clear molecular target for understanding and potentially manipulating baicalin's action.
  • Apoptosis as a mechanism for inhibition: At higher concentrations, baicalin's inhibitory effect on osteoclasts is linked to altered apoptosis-related protein expression, suggesting it can induce cell death in these bone-resorbing cells. This adds another layer to its mechanism of action.
  • In vivo validation of the dual effect: The LPS-induced calvarial osteolysis model in mice provides critical validation for the in vitro findings. This demonstrates that baicalin's dose-dependent effects translate to a complex biological system, reinforcing its potential therapeutic relevance.
  • Cautionary note on natural products: The study serves as a reminder that even natural compounds, often perceived as universally beneficial, can have complex and dose-dependent effects. This underscores the need for rigorous scientific investigation before widespread therapeutic use.

Key Results

  • In vitro:
    • Baicalin at concentrations of 0-1 µmol/L enhanced osteoclast differentiation, fusion, and bone resorption.
  • Baicalin at concentrations above 2 µmol/L inhibited osteoclast differentiation, fusion, and bone resorption.
  • Low baicalin concentrations activated the ERK/c-Fos/NFATc1 pathway, while high concentrations suppressed it.
  • High baicalin concentrations altered apoptosis-related protein expression, leading to increased apoptosis.
  • In vivo:
    • Low-dose baicalin (6 mg/kg) exacerbated LPS-induced calvarial osteolysis in mice.
  • High-dose baicalin (12 mg/kg) reduced LPS-induced calvarial osteolysis in mice.
  • Micro-CT and histological analyses confirmed these opposing effects on bone volume and osteoclast numbers.

Limitations and Future Work

  • Subcutaneous injection limitations: The authors acknowledge that subcutaneous injection in the animal model has limitations and suggest that intragastric administration might be a more appropriate method for future in vivo studies to better reflect systemic effects.
  • Mechanism of ERK regulation: While the study shows baicalin regulates ERK, the precise upstream signaling pathway responsible for this dual regulation remains to be fully elucidated. Further research into the common upstream signaling pathways linking ERK regulation and apoptosis induction is suggested.
  • Clinical translation: While the study demonstrates a dual effect, translating these findings into safe and effective clinical treatments for bone diseases will require further investigation into optimal dosing, delivery methods, and potential side effects in humans.
  • Broader therapeutic applications: The authors suggest that understanding these dual effects could guide the use of herbal remedies containing baicalin for various bone diseases.

Summary updated

Abstract

Osteoclasts (OC) are critical cells responsible for many bone diseases such as osteoporosis. It is of great interest to identify agents that can regulate the activity of OC to treat osteolytic bone diseases. In this study, we found that baicalin exerted a two-way regulatory effect on OC in a concentration-dependent manner in vitro and in vivo. In detail, baicalin at a low concentration (below 1 μmol/L) enhanced OC differentiation and bone resorption, but baicalin at a high concentration (above 2 μmol/L) exhibited inhibitory effects on OC. We demonstrated that baicalin at low concentrations enhanced the mitogen-activated protein kinase (MAPK) (ERK) signalling pathway and activated c-Fos and NFATc1 expression, and thus enhanced gene expression, OC differentiation and bone resorption. However, baicalin at higher levels not only suppressed ERK phosphorylation and c-fos and NFATc1 expression, but also altered the expression of apoptosis-related proteins, and therefore inhibiting OC function. This dual effect was further verified in an LPS-induced mouse calvarial osteolysis model, evidenced by enhanced osteolysis at a lower concentration but reduced bone loss at a higher concentration. Overall, our findings indicate that baicalin exerts dose-dependent effects on OC formation and function. Therefore, caution should be applied when using baicalin to treating OC-related bone diseases.
BibTeX
@article{lu2018dual,
  author = {Xuanyuan Lu and Wei He and Wanlei Yang and Jianlei Li and Weiqi Han and Qian Liu and Tan Zhang and Jiawei Jiang and An Qin and Yu Qian},
  title = {{Dual effects of baicalin on osteoclast differentiation and bone resorption}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2018},
  doi = {10.1111/jcmm.13785},
}
Figure